Harmony Biosciences (HRMY) announced the appointment of Adam Zaeske as executive VP and chief commercial officer, effective March 31. The company’s current CCO, Jeffrey Dierks, is voluntarily stepping down for personal reasons. Zaeske brings 25 years of global leadership across the pharmaceutical industry. At Harmony, Zaeske will be responsible for leading the company’s commercial organization, setting commercial strategy, driving market expansion in the U.S. and abroad. Zaeske most recently served as head of Central, South, and Eastern Europe at Takeda (TAK).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences price target raised to $44 from $42 at Mizuho
- Harmony Biosciences Earnings Call Highlights Growth and Challenges
- Harmony Biosciences price target lowered to $70 from $75 at H.C. Wainwright
- Harmony Biosciences price target raised to $33 from $31 at BofA
- Cautious Outlook: Sell Rating for Harmony Biosciences Due to Pipeline Concerns and Generic Competition Risks